PLEASANTON, CA--(Marketwire - January 28, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) announced today that it had demonstrated a positive therapeutic effect with the Company’s proprietary delipidated autologous virus vaccine in SIV-infected non-human primates. Primates infected with Simian Immunodeficiency Virus (SIV) are a widely-accepted model for HIV. Twelve animals ultimately qualified for this 22-month study -- 6 animals in the treatment arm and 6 placebo animals. Vaccination with autologous SIV, delipidated by Lipid Sciences’ proprietary process, led to an average 15.5 times viral load reduction in the treated animals. All 6 animals in the treatment arm of the study responded with drops in viral load in excess of 90%. While the study was not powered for statistical significance, it revealed an extremely strong trend of p=0.1, indicating the strong benefit of autologous delipidated viral vaccination in lowering viral loads in chronically-infected animals.
